IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Arthritis Research and Therapy

Volumn 19, Issue 1, 2017, Pages

  Lundström, Susanna L ^a   Hensvold, Aase H ^a,b   Rutishauser, Dorothea ^a   Klareskog, Lars ^a,b   Ytterberg, A Jimmy ^a   Zubarev, Roman A ^a   Catrina, Anca I ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; Complement; Glycosylation; Immunoglobulin; Methotrexate; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FC RECEPTOR; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; GALACTOSE; GLYCOSYLATED IGG; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PROTEIN GLYCOSYLATION; PROTEOMICS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SWEDEN; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BLOOD; GLYCOSYLATION; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; FEMALE; GALACTOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROTEOMICS;

EID: 85027139396     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-017-1389-7     Document Type: Article

References (35)

1. Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, et al. Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun. 2015;6:6637.
2. Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S, Amara K, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun. 2015;6:6651.
3. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1(3):237-43.
4. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008;105(50):19571-8.
5. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci. 2012;1253:170-80.
6. Collin M, Ehlers M. The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol. 2013;22(8):511-4.
7. de Jong SE, Selman MH, Adegnika AA, Amoah AS, van Riet E, Kruize YC, et al. IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Sci Rep. 2016;6:28207.
8. Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. 2015;74(1):234-41.
9. Collins ES, Galligan MC, Saldova R, Adamczyk B, Abrahams JL, Campbell MP, et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford). 2013;52(9):1572-82.
10. Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2239-48.
11. Lundstrom SL, Fernandes-Cerqueira C, Ytterberg AJ, Ossipova E, Hensvold AH, Jakobsson PJ, et al. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a Fab-peptide sequence. PLoS One. 2014;9(11):e113924.
12. Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010;62(6):1620-9.
13. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69(11):1898-906.
14. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
15. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges Jr SL, Ranganath VK, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65(8):1985-94.
16. Ercan A, Cui J, Hazen MM, Batliwalla F, Royle L, Rudd PM, et al. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther. 2012;14(2):R43.
17. Pasek M, Duk M, Podbielska M, Sokolik R, Szechinski J, Lisowska E, et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients - changes during therapy. Glycoconj J. 2006;23(7-8):463-71.
18. Gindzienska-Sieskiewicz E, Radziejewska I, Domyslawska I, Klimiuk PA, Sulik A, Rojewska J, et al. Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate. Adv Med Sci. 2016;61(2):193-7.
19. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011;63(1):26-36.
20. Hensvold AH, Joshua V, Li W, Larkin M, Qureshi F, Israelsson L, et al. Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res Ther. 2015;17:239.
21. van Gestel AM, Prevoo ML, Hof MA v 't, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40.
22. Aletaha D, Landewé R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008;59(10):1371-7.
23. Lundstrom SL, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka SK, Soininen H, et al. Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. J Alzheimers Dis. 2014;38(3):567-79.
24. Lyutvinskiy Y, Yang H, Rutishauser D, Zubarev RA. In silico instrumental response correction improves precision of label-free proteomics and accuracy of proteomics-based predictive models. Mol Cell Proteomics. 2013;12(8):2324-31.
25. Parekh RB, Roitt IM, Isenberg DA, Dwek RA, Ansell BM, Rademacher TW. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet. 1988;1(8592):966-9.
26. Nakagawa H, Hato M, Takegawa Y, Deguchi K, Ito H, Takahata M, et al. Detection of altered N-glycan profiles in whole serum from rheumatoid arthritis patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1-2):133-7.
27. Gornik I, Maravic G, Dumic J, Flogel M, Lauc G. Fucosylation of IgG heavy chains is increased in rheumatoid arthritis. Clin Biochem. 1999;32(8):605-8.
28. van de Geijn FE, Wuhrer M, Selman MH, Willemsen SP, de Man YA, Deelder AM, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther. 2009;11(6):R193.
29. Rouiller Y, Perilleux A, Marsaut M, Stettler M, Vesin MN, Broly H. Effect of hydrocortisone on the production and glycosylation of an Fc-fusion protein in CHO cell cultures. Biotechnol Prog. 2012;28(3):803-13.
30. Maguire TM, Coughlan CM, Seckl JR, Breen KC. The effect of corticosteroids on serum sialyltransferase enzyme activities in the rat. Biochim Biophys Acta. 1998;1379(1):23-8.
31. Saldova R, Huffman JE, Adamczyk B, Muzinic A, Kattla JJ, Pucic M, et al. Association of medication with the human plasma N-glycome. J Proteome Res. 2012;11(3):1821-31.
32. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. 1995;32(17-18):1311-8.
33. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 2005;21(6):1644-52.
34. Banda NK, Wood AK, Takahashi K, Levitt B, Rudd PM, Royle L, et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 2008;58(10):3081-9.
35. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem. 2008;376(1):1-12.